GTCM
OVID icon

Gyon Technologies Capital Management’s Ovid Therapeutics OVID Stock Holding History

Gyon Technologies Capital Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-88,008
Closed -$203K – 480
2020
Q4 		$203K Buy
88,008
+72,349
+462% +$337K 0.07% 321
2020
Q3 		$90K Buy
+15,659
New +$105K 0.07% 263

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gyon Technologies Capital Management's OVID Position: Q1 2021 in Review

Gyon Technologies Capital Management sold out of Ovid Therapeutics (OVID) in Q1 2021, closing a stake of 88,008 shares — an estimated $203K sold.

Gyon Technologies Capital Management first reported a position in OVID in Q3 2020 and held it in 2 quarters. The position peaked at $203K in Q4 2020. 88 funds tracked by Wall St. Rank hold OVID as of Q1 2021.

  • Gyon Technologies Capital Management reported no remaining Ovid Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 88,008 Ovid Therapeutics shares in Q1 2021, an estimated $203K.
  • Gyon Technologies Capital Management first reported a position in Ovid Therapeutics in Q3 2020 and held it in 2 quarters.
  • Gyon Technologies Capital Management's Ovid Therapeutics position peaked at $203K in Q4 2020.
  • 88 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2021.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2021, filed 17 May 2021.